logo

Clementia Pharmaceuticals Inc. (CMTA)



Trade CMTA now with
  Date
  Headline
12/12/2017 6:30:59 AM Clementia Begins Pivotal Phase 3 MOVE Trial For Palovarotene In Patients With Fibrodysplasia Ossificans Progressiva
11/14/2017 2:18:14 PM Wedbush Is Cutting Clementia Pharmaceuticals Inc. (CMTA) FY18 Estimate To -1.57 From -1.48
11/14/2017 2:17:51 PM Wedbush Is Cutting Clementia Pharmaceuticals Inc. (CMTA) Q4 18 Estimate To -0.43 From -0.40
11/14/2017 2:17:33 PM Wedbush Is Cutting Clementia Pharmaceuticals Inc. (CMTA) Q3 18 Estimate To -0.41 From -0.38
11/14/2017 2:17:14 PM Wedbush Is Lowering Clementia Pharmaceuticals Inc. (CMTA) Q2 18 Estimate To -0.38 From -0.36
11/14/2017 2:16:52 PM Wedbush Is Cutting Clementia Pharmaceuticals Inc. (CMTA) Q1 18 Estimate To -0.36 From -0.34
11/14/2017 2:16:32 PM Wedbush Is Lowering Clementia Pharmaceuticals Inc. (CMTA) FY17 Estimate To -29.19 From -27.64
11/14/2017 2:16:14 PM Wedbush Is Cutting Clementia Pharmaceuticals Inc. (CMTA) Q4 17 Estimate To -0.33 From -0.31
11/14/2017 2:15:47 PM Wedbush Reiterates Clementia Pharmaceuticals Inc. (CMTA) At Outperform With $26 Price Target
11/13/2017 8:10:55 AM Clementia Q3 Net Loss Widens To $39 Mln From $1.6 Mln Last Year
8/28/2017 7:17:59 AM Wedbush Starts Clementia Pharmaceuticals Inc. (CMTA) At Outperform With $26 Price Target